{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T21:20:18Z","timestamp":1648675218323},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2011,9,28]],"date-time":"2011-09-28T00:00:00Z","timestamp":1317168000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s11899-011-0100-3","type":"journal-article","created":{"date-parts":[[2011,9,27]],"date-time":"2011-09-27T04:01:41Z","timestamp":1317096101000},"page":"222-230","source":"Crossref","is-referenced-by-count":10,"title":["Update: Peripheral T-Cell Lymphomas"],"prefix":"10.1007","volume":"6","author":[{"given":"Kerry J.","family":"Savage","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,9,28]]},"reference":[{"issue":"5","key":"100_CR1","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","volume":"84","author":"N Harris","year":"1994","unstructured":"Harris N, Jaffe E, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84(5):1361\u201392.","journal-title":"Blood"},{"key":"100_CR2","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008.","edition":"4"},{"issue":"25","key":"100_CR3","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"International T-Cell Lymphoma Project","year":"2008","unstructured":"International T-Cell Lymphoma Project. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124\u201330.","journal-title":"J Clin Oncol"},{"key":"100_CR4","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1182\/blood-2006-04-017632","volume":"108","author":"J Dupuis","year":"2006","unstructured":"Dupuis J, Emile J, Mounier N, et al. Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: a Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA) study. Blood. 2006;108:4163\u20139.","journal-title":"Blood"},{"issue":"12","key":"100_CR5","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","volume":"117","author":"DD Weisenburger","year":"2011","unstructured":"\u2022\u2022 Weisenburger DD, Savage KJ, Harris NL, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood. 2011;117(12):3402\u20138. This evaluation of prognostic factors in PTCL-NOS comes from the International Peripheral T-Cell Lymphoma Project.","journal-title":"Blood"},{"issue":"5","key":"100_CR6","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0002-9440(10)63742-X","volume":"164","author":"A Zettl","year":"2004","unstructured":"Zettl A, Rudiger T, Konrad MA, et al. Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations. Am J Pathol. 2004;164(5):1837\u201348.","journal-title":"Am J Pathol"},{"issue":"1","key":"100_CR7","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/gcc.20386","volume":"46","author":"C Thorns","year":"2007","unstructured":"Thorns C, Bastian B, Pinkel D, et al. Chromosomal aberrations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma unspecified: a matrix-based CGH approach. Genes Chromosom Cancer. 2007;46(1):37\u201344.","journal-title":"Genes Chromosom Cancer"},{"issue":"1","key":"100_CR8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1365-2559.2010.03704.x","volume":"58","author":"L Leval de","year":"2011","unstructured":"de Leval L, Gaulard P. Pathology and biology of peripheral T-cell lymphomas. Histopathology. 2011;58(1):49\u201368.","journal-title":"Histopathology"},{"issue":"Supp 5","key":"100_CR9","first-page":"124a","volume":"16","author":"B Ballester","year":"2005","unstructured":"Ballester B, Gisselbrecht C, Gaulard P, et al. Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Ann Oncol. 2005;16(Supp 5):124a.","journal-title":"Ann Oncol"},{"issue":"5","key":"100_CR10","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1182\/blood-2009-06-227579","volume":"115","author":"J Iqbal","year":"2010","unstructured":"\u2022\u2022 Iqbal J, Weisenburger DD, Greiner TC, et al. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood. 2010;115(5):1026\u201336. This gene expression profiling study with a focus on AILT identifies molecular signatures associated with a favorable or unfavorable prognosis.","journal-title":"Blood"},{"issue":"11","key":"100_CR11","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1182\/blood-2006-10-055145","volume":"109","author":"L Leval de","year":"2007","unstructured":"de Leval L, Rickman DS, Thielen C, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood. 2007;109(11):4952\u201363.","journal-title":"Blood"},{"issue":"10","key":"100_CR12","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","volume":"15","author":"KJ Savage","year":"2004","unstructured":"Savage KJ, Chhanabhai M, Gascoyne RD, et al. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol. 2004;15(10):1467\u201375.","journal-title":"Ann Oncol"},{"issue":"7","key":"100_CR13","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","volume":"103","author":"A Gallamini","year":"2004","unstructured":"Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103(7):2474\u20139.","journal-title":"Blood"},{"issue":"9","key":"100_CR14","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1182\/blood-2007-08-105759","volume":"111","author":"N Mourad","year":"2008","unstructured":"Mourad N, Mounier N, Briere J, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA) trials. Blood. 2008;111(9):4463\u201370.","journal-title":"Blood"},{"key":"100_CR15","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1126\/science.8122112","volume":"1994","author":"SW Morris","year":"1994","unstructured":"Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin\u2019s lymphoma. Science. 1994;1994:1281\u20134.","journal-title":"Science"},{"key":"100_CR16","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2141.1990.tb02560.x","volume":"74","author":"D Mason","year":"1990","unstructured":"Mason D, Bastard C, Rimokh R, et al. CD30-positive large cell lymphomas (\u201cKi-1 lymphoma\u201d) are associated with a chromosomal translocation involving 5q35. Br J Haematol. 1990;74:161\u20138.","journal-title":"Br J Haematol"},{"issue":"5","key":"100_CR17","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1182\/blood-2006-06-028969","volume":"109","author":"L Lamant","year":"2007","unstructured":"Lamant L, de Reynies A, Duplantier MM, et al. Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. Blood. 2007;109(5):2156\u201364.","journal-title":"Blood"},{"issue":"37","key":"100_CR18","doi-asserted-by":"crossref","first-page":"16228","DOI":"10.1073\/pnas.1009719107","volume":"107","author":"O Merkel","year":"2010","unstructured":"Merkel O, Hamacher F, Laimer D, et al. Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma. Proc Natl Acad Sci USA. 2010;107(37):16228\u201333.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"21","key":"100_CR19","first-page":"322","volume":"116","author":"D Sibon","year":"2010","unstructured":"\u2022 Sibon D, Fournier M, Briere J, et al. Prognostic factors and long term outcome of 138 adults with systemic anaplastic large-cell lymphoma: a retrospective study by the Groupe d\u2019Etude Des Lymphomes De l\u2019Adulte (GELA). Blood (ASH Annual Meeting Abstracts). 2010;116(21):322. This large study of ALCL patients identified the importance of age as well as ALK status for prognosis.","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"10","key":"100_CR20","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1182\/blood-2004-03-1037","volume":"104","author":"I Bonzheim","year":"2004","unstructured":"Bonzheim I, Geissinger E, Roth S, et al. Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell receptor signaling. Blood. 2004;104(10):3358\u201360.","journal-title":"Blood"},{"issue":"5","key":"100_CR21","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1365-2141.2007.06924.x","volume":"140","author":"I Salaverria","year":"2008","unstructured":"Salaverria I, Bea S, Lopez-Guillermo A, et al. Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas. Br J Haematol. 2008;140(5):516\u201326.","journal-title":"Br J Haematol"},{"issue":"3","key":"100_CR22","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1182\/blood-2010-08-303305","volume":"117","author":"AL Feldman","year":"2011","unstructured":"\u2022 Feldman AL, Dogan A, Smith DI, et al. Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood. 2011;117(3):915\u20139. This article reports on a novel technique to discover recurrent translocation in ALK-negative ALCL.","journal-title":"Blood"},{"issue":"4","key":"100_CR23","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/modpathol.2010.225","volume":"24","author":"DA Wada","year":"2011","unstructured":"Wada DA, Law ME, Hsi ED, et al. Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies. Mod Pathol. 2011;24(4):596\u2013605.","journal-title":"Mod Pathol"},{"issue":"5","key":"100_CR24","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1046\/j.1365-2559.2003.01726.x","volume":"43","author":"RL Berge ten","year":"2003","unstructured":"ten Berge RL, de Bruin PC, Oudejans JJ, et al. ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified. Histopathology. 2003;43(5):462\u20139.","journal-title":"Histopathology"},{"issue":"9","key":"100_CR25","first-page":"2993","volume":"96","author":"R Suzuki","year":"2000","unstructured":"Suzuki R, Kagami Y, Takeuchi K, et al. Prognostic significance of CD56 expression for ALK-positive and ALK- negative anaplastic large-cell lymphoma of T\/null cell phenotype. Blood. 2000;96(9):2993\u20133000.","journal-title":"Blood"},{"key":"100_CR26","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1182\/blood.V93.11.3913","volume":"93","author":"R Gascoyne","year":"1999","unstructured":"Gascoyne R, Aoun P, Wu D, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood. 1999;93:3913\u201321.","journal-title":"Blood"},{"issue":"12","key":"100_CR27","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","volume":"111","author":"KJ Savage","year":"2008","unstructured":"\u2022 Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111(12):5496\u2013504. This is a detailed study from the International Peripheral T-Cell Lymphoma Project regarding ALCL.","journal-title":"Blood"},{"issue":"8","key":"100_CR28","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.3109\/10428194.2011.574755","volume":"52","author":"L Popplewell","year":"2011","unstructured":"Popplewell L, Thomas SH, Huang Q, et al. Primary anaplastic large-cell lymphoma associated with breast implants. Leuk Lymphoma. 2011;52(8):1481\u20137.","journal-title":"Leuk Lymphoma"},{"key":"100_CR29","doi-asserted-by":"crossref","unstructured":"Lazzeri D, Agostini T, Bocci G, et al. ALK-1-negative anaplastic large cell lymphoma associated with breast implants: a new clinical entity. Clin Breast Cancer. 2011 May 11 (Epub ahead of print).","DOI":"10.1016\/j.clbc.2011.03.020"},{"key":"100_CR30","doi-asserted-by":"crossref","unstructured":"Kim B, Roth C, Young VL, et al. Anaplastic large cell lymphoma and breast implants: results from a structured expert consultation process. Plast Reconstr Surg. 2011 May 12 (Epub ahead of print).","DOI":"10.1200\/jco.2011.29.15_suppl.e18535"},{"issue":"14","key":"100_CR31","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","volume":"328","author":"RI Fisher","year":"1993","unstructured":"Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993;328(14):1002\u20136.","journal-title":"N Engl J Med"},{"issue":"2","key":"100_CR32","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2141.2009.07606.x","volume":"145","author":"L Jiang","year":"2009","unstructured":"Jiang L, Yuan CM, Hubacheck J, et al. Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy. Br J Haematol. 2009;145(2):173\u20139.","journal-title":"Br J Haematol"},{"issue":"2","key":"100_CR33","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2141.2010.08329.x","volume":"151","author":"A Simon","year":"2010","unstructured":"Simon A, Peoch M, Casassus P, et al. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP\/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. Br J Haematol. 2010;151(2):159\u201366.","journal-title":"Br J Haematol"},{"issue":"18","key":"100_CR34","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","volume":"116","author":"N Schmitz","year":"2010","unstructured":"\u2022 Schmitz N, Tr\u00fcmper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010;116(18):3418\u201325. This is a retrospective analysis of prospective studies evaluating the impact of etoposide on the outcome of PTCL.","journal-title":"Blood"},{"issue":"7","key":"100_CR35","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1093\/annonc\/mdq635","volume":"22","author":"HC Kluin-Nelemans","year":"2011","unstructured":"Kluin-Nelemans HC, van Marwijk Kooy M, Lugtenburg PJ, et al. Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. Ann Oncol. 2011;22(7):1595\u2013600.","journal-title":"Ann Oncol"},{"issue":"1","key":"100_CR36","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00280-007-0469-9","volume":"60","author":"JG Kim","year":"2007","unstructured":"Kim JG, Sohn SK, Chae YS, et al. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemother Pharmacol. 2007;60(1):129\u201334.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"15s","key":"100_CR37","doi-asserted-by":"crossref","first-page":"8045a","DOI":"10.1200\/jco.2010.28.15_suppl.8045","volume":"28","author":"FM Foss","year":"2010","unstructured":"Foss FM, Sjak-Shie A, Goy A, et al. Phase II study of denileukin diftitox with CHOP chemotherapy in newly diagnosed PTCL: CONCEPT trial. J Clin Oncol. 2010;28(15s):8045a.","journal-title":"J Clin Oncol"},{"issue":"21","key":"100_CR38","first-page":"2829","volume":"116","author":"G Corazzelli","year":"2010","unstructured":"Corazzelli G, Frigeri F, Marcacci G, et al. Gemcitabine, Ifosfamide, Oxaliplatin (GIFOX) as first-line treatment in high-risk peripheral T-Cell\/NK lymphomas: a phase II trial. Blood (ASH Annual Meeting Abstracts). 2010;116(21):2829.","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"Suppl 4 111a","key":"100_CR39","first-page":"5","volume":"22","author":"D Mahadevan","year":"2011","unstructured":"Mahadevan D, Unger JM, Persky DO, et al. Phase II trial of Cisplatin plus Etoposide plus Gemcitabine plus Solumedrol (PEGS) in peripheral T-cell non-Hodgkin lymphoma (SWOG S0350). Ann Oncol. 2011;22(Suppl 4 111a):5\u2013282.","journal-title":"Ann Oncol"},{"issue":"6","key":"100_CR40","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2010-09-307454","volume":"117","author":"A Jaccard","year":"2011","unstructured":"\u2022 Jaccard A, Gachard N, Marin B, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK\/T-cell lymphoma, a phase 2 study. Blood. 2011;117(6):1834\u20139. This is a report of a promising new L-asparaginase combination for extranodal NK\/T-cell lymphoma.","journal-title":"Blood"},{"issue":"10","key":"100_CR41","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/cncr.20999","volume":"103","author":"MP Escalon","year":"2005","unstructured":"Escalon MP, Liu NS, Yang Y, et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma. Cancer. 2005;103(10):2091\u20138.","journal-title":"Cancer"},{"issue":"supplement 2","key":"100_CR42","first-page":"437","volume":"94","author":"F d\u2019Amore","year":"2009","unstructured":"\u2022 d\u2019Amore F, Relander T, Lauritzsen GF, et al. Dose-dense induction followed by autologous stem cell transplant (ASCT) leads to sustained remissions in a large fraction of patients with previously untreated peripheral T-cell lymphomas (PTCLs)\u2014overall and subtype-specific results of a phase II study from Nordic Lymphoma Group. Haematologica. 2009;94(supplement 2):437. These are preliminary results of large phase II prospective study of ASCT in untreated PTCLs.","journal-title":"Haematologica"},{"issue":"21","key":"100_CR43","first-page":"3566","volume":"116","author":"T Relander","year":"2010","unstructured":"Relander T, Lauritzsen GF, Jantunen E, et al. Favorable outcome in ALK-negative anaplastic large-cell lymphoma following intensive induction chemotherapy and Autologous Stem Cell Transplantation (ASCT): a prospective study by the Nordic Lymphoma Group (NLG-T-01). Blood (ASH Annual Meeting Abstracts). 2010;116(21):3566.","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"100_CR44","doi-asserted-by":"crossref","first-page":"320624","DOI":"10.1155\/2010\/320624","volume":"2010","author":"P Reimer","year":"2010","unstructured":"Reimer P. Impact of autologous and allogeneic stem cell transplantation in peripheral T-cell lymphomas. Adv Hematol. 2010;2010:320624. doi: 10.1155\/2010\/320624 .","journal-title":"Adv Hematol"},{"issue":"14","key":"100_CR45","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1200\/JCO.2007.14.1366","volume":"26","author":"S Gouill Le","year":"2008","unstructured":"\u2022 Le Gouill S, Milpied N, Buzyn A, et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol. 2008;26(14):2264\u201371. This is the largest study evaluating the outcome of PTCL patients treated with allogeneic transplantation.","journal-title":"J Clin Oncol"},{"issue":"7","key":"100_CR46","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1093\/annonc\/mdq698","volume":"22","author":"ED Jacobsen","year":"2011","unstructured":"Jacobsen ED, Kim HT, Ho VT, et al. A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides\/Sezary syndrome. Ann Oncol. 2011;22(7):1608\u201313.","journal-title":"Ann Oncol"},{"issue":"26","key":"100_CR47","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1200\/JCO.2008.20.8470","volume":"27","author":"OA O\u2019Connor","year":"2009","unstructured":"O\u2019Connor OA, Horwitz S, Hamlin P, et al. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol. 2009;27(26):4357\u201364.","journal-title":"J Clin Oncol"},{"issue":"9","key":"100_CR48","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","volume":"29","author":"OA O\u2019Connor","year":"2011","unstructured":"\u2022 O\u2019Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral t-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29(9):1182\u20139. This is the first study evaluating a novel agent specifically in relapsed\/refractory PTCL.","journal-title":"J Clin Oncol"},{"issue":"22","key":"100_CR49","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","volume":"117","author":"RL Piekarz","year":"2011","unstructured":"\u2022 Piekarz RL, Frye R, Prince HM, et al. Phase II trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011;117(22):5827\u201334. This phase II study evaluates romidepsin in relapsed\/refractory PTCL.","journal-title":"Blood"},{"issue":"21","key":"100_CR50","first-page":"114","volume":"116","author":"B Coiffier","year":"2010","unstructured":"Coiffier B, Pro B, Prince HM, et al. Final results from a pivotal, multicenter, international, open-label, phase 2 study of romidepsin in progressive or relapsed Peripheral T-Cell Lymphoma (PTCL) following prior systemic therapy. Blood (ASH Annual Meeting Abstracts). 2010;116(21):114.","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"22","key":"100_CR51","first-page":"920","volume":"114","author":"B Pohlman","year":"2009","unstructured":"Pohlman B, Advani R, Duvic M, et al. Final results of a phase II trial of belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma. Blood (ASH Annual Meeting Abstracts). 2009;114(22):920.","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"11","key":"100_CR52","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1182\/blood.V104.11.2637.2637","volume":"104","author":"A Forero-Torres","year":"2004","unstructured":"Forero-Torres A, Bernstein S, Gopal A, et al. SGN-30 (anti-CD30 monoclonal antibody) is active and well tolerated in patients with refractory or recurrent systemic anaplastic large cell lymphoma. Blood. 2004;104(11):2637.","journal-title":"Blood"},{"issue":"Supp 4","key":"100_CR53","first-page":"5","volume":"22","author":"A Shustov","year":"2011","unstructured":"\u2022 Shustov A, Advani R, Brice P, et al. Durable remissions with SGN-et (brentuximab vedotin): updated results of a phase 2 study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). Ann Oncol. 2011;22(Supp 4):5\u2013282. This phase II study evaluated brentuximab vedotin in relapsed\/refractory ALCL.","journal-title":"Ann Oncol"},{"issue":"11","key":"100_CR54","first-page":"2005","volume":"112","author":"AM Evens","year":"2008","unstructured":"Evens AM, Gordon LI, Patton D, et al. Phase I results of combination gemcitabine and bortezomib (Velcade(R)) for relapsed\/refractory nodal T-cell Non-Hodgkin Lymphoma (T-NHL) and Aggressive B-Cell NHL (B-NHL). Blood (ASH Annual Meeting Abstracts). 2008;112(11):2005.","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"Suppl 1","key":"100_CR55","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1053\/j.seminhematol.2010.01.014","volume":"47","author":"OA O\u2019Connor","year":"2010","unstructured":"O\u2019Connor OA. Novel agents in development for peripheral T-cell lymphoma. Semin Hematol. 2010;47 Suppl 1:S11\u20134.","journal-title":"Semin Hematol"},{"issue":"21","key":"100_CR56","first-page":"1791","volume":"116","author":"SJ Kim","year":"2010","unstructured":"Kim SJ, Eom H-S, Kim JS, et al. The efficacy of Bortezomib-CHOP in patients with advanced stage T or NK\/T cell lymphomas: the results of multicenter phase II study [abstract]. ASH Annu Meet Abstracts. 2010;116(21):1791.","journal-title":"ASH Annu Meet Abstracts"},{"issue":"15S","key":"100_CR57","doi-asserted-by":"crossref","first-page":"8554a","DOI":"10.1200\/jco.2009.27.15_suppl.8554","volume":"27","author":"A Delmer","year":"2009","unstructured":"Delmer A, Fitoussi P, Gaulard P, et al. A phase II study of bortezomib in combination with intensified CHOP-like regimen (ACVBP) in patients with previously untreated T-cell lymphoma: Results of the GELA LNH05\u20131\u00a0T trial. J Clin Oncol. 2009;27(15S):8554a.","journal-title":"J Clin Oncol"},{"issue":"19","key":"100_CR58","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1002\/cncr.25377","volume":"116","author":"G Dueck","year":"2010","unstructured":"Dueck G, Chua N, Prasad A, et al. Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer. 2010;116(19):4541\u20138.","journal-title":"Cancer"},{"issue":"8","key":"100_CR59","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.3109\/10428194.2011.573031","volume":"52","author":"PL Zinzani","year":"2011","unstructured":"Zinzani PL, Pellegrini C, Broccoli A, et al. Lenalidomide monotherapy for relapsed\/refractory peripheral T-cell lymphoma not otherwise specified. Leuk Lymphoma. 2011;52(8):1585\u20138.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"100_CR60","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s11899-009-0030-5","volume":"4","author":"HM O\u2019Leary","year":"2009","unstructured":"O\u2019Leary HM, Savage KJ. Update on the World Health Organization classification of peripheral T-cell lymphomas. Curr Hematol Malig Rep. 2009;4(4):227\u201335.","journal-title":"Curr Hematol Malig Rep"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-011-0100-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-011-0100-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-011-0100-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T20:09:35Z","timestamp":1638907775000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-011-0100-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,28]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["100"],"URL":"https:\/\/doi.org\/10.1007\/s11899-011-0100-3","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,28]]}}}